Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.

Inclusion criteria

• ✓. Signed and dated informed consent prior to any study assessment;
• ✓. Age 15-75 years inclusive, female or male;
• ✓. Diagnosed as asthma according to the guideline for the prevention and treatment of bronchial asthma in China (version 2016), with duration for more than 1 years;
• ✓. Have had at least one severe asthma exacerbations(requiring systemic steroid use) in the previous one year;
• ✓. At screening, serum total IgE level 60-1500IU/ml and body weight 20-150kg.
• ✓. Receiving seretide(fluticasone\>250ug/day) or symbicort(budesonide\>400ug/day) for at least 3 months and stable dose for at least 4 weeks prior to screening. Asthma symptom control level is still partly controlled or uncontrolled. Detailed drugs and usage are one of the following: Seretide 50/250ug 1 inhalation bid；Seretide 50/500ug 1 inhalation bid；Symbicort 160/4.5ug 2 inhalations bid or Symbicort 320/9ug 1 inhalation bid.
• ✓. None of other asthma controller medications other than seretide or symbicort including systemic steroid, leukotriene modifiers, theophylline, histamine1 receptor blockers, anticholinergic drugs, traditional Chinese medicine and so on have been used 2 weeks prior to screening.
• ✓. At screening, FEV1 \< 80% of the predicted normal value.